STI Stock Trade Intelligence
MVP

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

Health Care · ASX:MVP
$0.4150
▼ -3.49%
Market cap
$47M
Turnover
$48,827
Last price
$0.4150
Day change
-3.49%
Announcements
7
Range, past year
Open 0.560 · Low 0.365 · Now 0.415 · High 0.765
Open MVP in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

MVP momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
34/100
Wyckoff phase
Accumulation5d
Trend stage
Neutral
1 Day
-3.5%
1 Week
+0.0%
1 Month
+1.2%
1 Year
-25.2%
RSI
52
Avg daily range
5.0%

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED scores 34 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 5 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently outperforming and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -31.8%
  • Thin liquidity
  • Risk rating: High
  • Composite downside risk elevated
MVP appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

MVP announcements

Recent price-sensitive releases.
  • 2026-10-15 Appendix 4C and Quarterly Activity Report -30 September 2026 Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-10-15 CEO Transition CEO/Managing Director - Appointment Resignation | Web Cast
  • 2026-08-20 FY26 Full year Results Investor Presentation Company Presentation | Preliminary Final Report
  • 2026-08-20 MVP Announces FY26 Full Year Results Preliminary Final Report
  • 2026-08-20 FY26 Full Year Results Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
  • 2026-07-24 Appendix 4C and Quarterly Activity Report 30 June 2026 Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
  • 2026-04-24 Appendix 4C and Quarterly Activity Report 31 March 2026
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.